Cargando…
Immune life history, vaccination, and the dynamics of SARS-CoV-2 over the next 5 years
The future trajectory of the coronavirus disease 2019 (COVID-19) pandemic hinges on the dynamics of adaptive immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); however, salient features of the immune response elicited by natural infection or vaccination are still uncertai...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for the Advancement of Science
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7857410/ https://www.ncbi.nlm.nih.gov/pubmed/32958581 http://dx.doi.org/10.1126/science.abd7343 |
_version_ | 1783646442078863360 |
---|---|
author | Saad-Roy, Chadi M. Wagner, Caroline E. Baker, Rachel E. Morris, Sinead E. Farrar, Jeremy Graham, Andrea L. Levin, Simon A. Mina, Michael J. Metcalf, C. Jessica E. Grenfell, Bryan T. |
author_facet | Saad-Roy, Chadi M. Wagner, Caroline E. Baker, Rachel E. Morris, Sinead E. Farrar, Jeremy Graham, Andrea L. Levin, Simon A. Mina, Michael J. Metcalf, C. Jessica E. Grenfell, Bryan T. |
author_sort | Saad-Roy, Chadi M. |
collection | PubMed |
description | The future trajectory of the coronavirus disease 2019 (COVID-19) pandemic hinges on the dynamics of adaptive immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); however, salient features of the immune response elicited by natural infection or vaccination are still uncertain. We use simple epidemiological models to explore estimates for the magnitude and timing of future COVID-19 cases, given different assumptions regarding the protective efficacy and duration of the adaptive immune response to SARS-CoV-2, as well as its interaction with vaccines and nonpharmaceutical interventions. We find that variations in the immune response to primary SARS-CoV-2 infections and a potential vaccine can lead to markedly different immune landscapes and burdens of critically severe cases, ranging from sustained epidemics to near elimination. Our findings illustrate likely complexities in future COVID-19 dynamics and highlight the importance of immunological characterization beyond the measurement of active infections for adequately projecting the immune landscape generated by SARS-CoV-2 infections. |
format | Online Article Text |
id | pubmed-7857410 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | American Association for the Advancement of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-78574102021-02-05 Immune life history, vaccination, and the dynamics of SARS-CoV-2 over the next 5 years Saad-Roy, Chadi M. Wagner, Caroline E. Baker, Rachel E. Morris, Sinead E. Farrar, Jeremy Graham, Andrea L. Levin, Simon A. Mina, Michael J. Metcalf, C. Jessica E. Grenfell, Bryan T. Science Research Articles The future trajectory of the coronavirus disease 2019 (COVID-19) pandemic hinges on the dynamics of adaptive immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); however, salient features of the immune response elicited by natural infection or vaccination are still uncertain. We use simple epidemiological models to explore estimates for the magnitude and timing of future COVID-19 cases, given different assumptions regarding the protective efficacy and duration of the adaptive immune response to SARS-CoV-2, as well as its interaction with vaccines and nonpharmaceutical interventions. We find that variations in the immune response to primary SARS-CoV-2 infections and a potential vaccine can lead to markedly different immune landscapes and burdens of critically severe cases, ranging from sustained epidemics to near elimination. Our findings illustrate likely complexities in future COVID-19 dynamics and highlight the importance of immunological characterization beyond the measurement of active infections for adequately projecting the immune landscape generated by SARS-CoV-2 infections. American Association for the Advancement of Science 2020-11-13 2020-09-21 /pmc/articles/PMC7857410/ /pubmed/32958581 http://dx.doi.org/10.1126/science.abd7343 Text en Copyright © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works https://creativecommons.org/licenses/by/4.0/ https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution license (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Articles Saad-Roy, Chadi M. Wagner, Caroline E. Baker, Rachel E. Morris, Sinead E. Farrar, Jeremy Graham, Andrea L. Levin, Simon A. Mina, Michael J. Metcalf, C. Jessica E. Grenfell, Bryan T. Immune life history, vaccination, and the dynamics of SARS-CoV-2 over the next 5 years |
title | Immune life history, vaccination, and the dynamics of SARS-CoV-2 over the next 5 years |
title_full | Immune life history, vaccination, and the dynamics of SARS-CoV-2 over the next 5 years |
title_fullStr | Immune life history, vaccination, and the dynamics of SARS-CoV-2 over the next 5 years |
title_full_unstemmed | Immune life history, vaccination, and the dynamics of SARS-CoV-2 over the next 5 years |
title_short | Immune life history, vaccination, and the dynamics of SARS-CoV-2 over the next 5 years |
title_sort | immune life history, vaccination, and the dynamics of sars-cov-2 over the next 5 years |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7857410/ https://www.ncbi.nlm.nih.gov/pubmed/32958581 http://dx.doi.org/10.1126/science.abd7343 |
work_keys_str_mv | AT saadroychadim immunelifehistoryvaccinationandthedynamicsofsarscov2overthenext5years AT wagnercarolinee immunelifehistoryvaccinationandthedynamicsofsarscov2overthenext5years AT bakerrachele immunelifehistoryvaccinationandthedynamicsofsarscov2overthenext5years AT morrissineade immunelifehistoryvaccinationandthedynamicsofsarscov2overthenext5years AT farrarjeremy immunelifehistoryvaccinationandthedynamicsofsarscov2overthenext5years AT grahamandreal immunelifehistoryvaccinationandthedynamicsofsarscov2overthenext5years AT levinsimona immunelifehistoryvaccinationandthedynamicsofsarscov2overthenext5years AT minamichaelj immunelifehistoryvaccinationandthedynamicsofsarscov2overthenext5years AT metcalfcjessicae immunelifehistoryvaccinationandthedynamicsofsarscov2overthenext5years AT grenfellbryant immunelifehistoryvaccinationandthedynamicsofsarscov2overthenext5years |